Chronic reboxetine desensitizes terminal but not somatodendritic α2-adrenoceptors controlling noradrenaline release in the rat dorsal hippocampus

Neuropsychopharmacology

Volumn 30, Issue 6, 2005, Pages 1048-1055

  Parini, Stefania ^a   Renoldi, Giuliano ^a   Battaglia, Angelo ^b   Invernizzi, Roberto W ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b PFIZER INC   (United States)

Author keywords

Antidepressants; Autoreceptor desensitization; Clonidine; Locus coeruleus; Microdialysis; Noradrenaline reuptake inhibitors

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CLONIDINE; DRUG VEHICLE; NORADRENALIN; REBOXETINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DENDRITE; DESENSITIZATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; LOCUS CERULEUS; MALE; MICRODIALYSIS; NONHUMAN; NORADRENALIN RELEASE; OSMOTIC PUMP; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SOMATIC CELL;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CLONIDINE; DENDRITES; EXTRACELLULAR SPACE; HIPPOCAMPUS; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, INTRAPERITONEAL; LOCUS COERULEUS; MALE; MICROINJECTIONS; MORPHOLINES; NOREPINEPHRINE; RATS; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 19344368552     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300661     Document Type: Article

References (50)

1. Adell A, Artigas F (1991). Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo brain microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 343: 237-244.
2. Agneter E, Drobny H, Singer EA (1993). Central alpha 2-autoreceptors: agonist dissociation constants and recovery after irreversible inactivation. Br J Pharmacol 108: 370-375.
3. Anden NE, Grabowska M, Strombom U (1976). Different alpha-adrenoreceptors in the central nervous system mediating biochemical and functional effects of clonidine and receptor blocking agents. Naunyn Schmiedebergs Arch Pharmacol 292: 43-52.
4. Artigas F, Romero L, de Montigny C, Blier P (1996). Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19: 378-383.
5. Blier P, de Montigny C (1985). Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors. Neuroscience 16: 949-955.
6. Blier P, de Montigny C (1994). Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15: 220-226.
7. Blier P, de Montigny C, Azzaro AJ (1986). Effect of repeated amiflamine administration on serotonergic and noradrenergic neurotransmission: electrophysiological studies in the rat CNS. Naunyn Schmiedebergs Arch Pharmacol 334: 253-260.
8. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH et al (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27: 699-711.
9. 3H]noradrenaline release to calcium but not to clonidine. Brain Res 372: 253-259.
10. Cedarbaum JM, Aghajanian GK (1976). Noradrenergic neurons of the locus coeruleus: inhibition by epinephrine and activation by the alpha-antagonist piperoxane. Brain Res 112: 413-419.
11. Charney DS, Price LH, Heninger GR (1986). Desipramineyohimbine combination treatment of refractory depression. Implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch Gen Psychiatry 43: 1155-1161.
12. Dazzi L, Spiga F, Pira L, Ladu S, Vacca G, Rivano A et al (2001). Inhibition of stress- or anxiogenic-drug-induced increases in dopamine release in the rat prefrontal cortex by long-term treatment with antidepressant drugs. J Neurochem 76: 1212-1220.
13. Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR, Gelenberg AJ et al (1993). Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 29: 389-396.
14. Delgado PL, Moreno FA, Onate L, Gelenberg AJ (2002). Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int J Neuropsychopharmacol 5: 63-66.
15. Dennis T, L'Heureux R, Carter C, Scatton B (1987). Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J Pharmacol Exp Ther 241: 642-649.
16. Dostert P, Benedetti MS, Poggesi I (1997). Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 7(Suppl 1): S23-S35 (discussion S71-S73).
17. Florin-Lechner SM, Druhan JP, Aston-Jones G, Valentino RJ (1996). Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus. Brain Res 742: 89-97.
18. Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ (1997). Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem 69: 2616-2629.
19. Grandoso L, Pineda J, Ugedo L (2004). Comparative study of the effects of desipramine and reboxetine on locus coeruleus neurons in rat brain slices. Neuropharmacology 46: 815-823.
20. Invernizzi R, Belli S, Samanin R (1992). Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 584: 322-324.
21. 1A receptors. Eur J Pharmacol 260: 243-246.
22. 2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog Psychopharmacol Biol Psychiatry 28: 819-827.
23. Invernizzi RW, Parini S, Sacchetti G, Fracasso C, Caccia S, Annoni K et al (2001). Chronic treatment with reboxetine by osmotic pumps facilitates its effect on extracellular noradrenaline and may desensitize alpha(2)-adrenoceptors in the prefrontal cortex. Br J Pharmacol 132: 183-188.
24. Lacroix D, Blier P, Curet O, de Montigny C (1991). Effects of long-term desipramine administration on noradrenergic neurotransmission: electrophysiological studies in the rat brain. J Pharmacol Exp Ther 257: 1081-1090.
25. Lauritzen L, Clemmesen L, Klysner R, Loldrup D, Lunde M, Schaumburg E et al (1992). Combined treatment with imipramine and mianserin. A controlled pilot study. Pharmacopsychiatry 25: 182-186.
26. L'Heureux R, Dennis T, Curet O, Scatton B (1986). Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis: effects of drugs affecting noradrenergic transmission. J Neurochem 46: 1794-1801.
27. Lorang D, Amara SG, Simerly RB (1994). Cell-type-specific expression of catecholamine transporters in the rat brain. J Neurosci 14: 4903-4914.
28. Mateo Y, Fernandez-Pastor B, Meana JJ (2001). Acute and chronic effects of desipramine and clorgyline on alpha(2)-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br J Pharmacol 133: 1362-1370.
29. Mateo Y, Pineda J, Meana JJ (1998). Somatodendritic alpha2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. J Neurochem 71: 790-798.
30. Miller HL, Delgado PL, Salomon RM, Heninger GR, Charney DS (1996). Effects of alpha-methyl-para-tyrosine (AMPT) in drug-free depressed patients. Neuropsychopharmacology 14: 151-157.
31. Moore RY, Bloom FE (1978). Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. Annu Rev Neurosci 1: 129-169.
32. National Research Council (1996). Guide for the Care and Use of Laboratory Animals. National Academy Press: Washington, DC.
33. Osman OT, Rudorfer MV, Potter WZ (1989). Chronic alpha-2 antagonism increases norepinephrine, blocks GH release and is antidepressant. Biol Psychiatry 25: 197A.
34. Page ME, Lucki I (2002). Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology 27: 237-247.
35. Paxinos G, Watson C (1982). The Rat Brain in Stereotaxic Coordinates. Academic Press: Sidney.
36. Pineda J, Ruiz-Ortega JA, Ugedo L (1997). Receptor reserve and turnover of alpha-2 adrenoceptors that mediate the clonidine-induced inhibition of rat locus coeruleus neurons in vivo. J Pharmacol Exp Ther 281: 690-698.
37. Robinson TE, Whishaw IQ (1988). Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res 450: 209-224.
38. Sacchetti G, Bernini M, Bianchetti A, Parini S, Invernizzi RW, Samanin R (1999). Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain. Br J Pharmacol 128: 1332-1338.
39. Sacchetti G, Bernini M, Gobbi M, Parini S, Pirona L, Mennini T et al (2001). Chronic treatment with desipramine facilitates its effect on extracellular noradrenaline in the rat hippocampus: studies on the role of presynaptic alpha2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 363: 66-72.
40. Schmauss M, Laakmann G, Dieterle D (1988), Effects of alpha 2-receptor blockade in addition to tricyclic antidepressants in therapy-resistant depression. J Clin Psychopharmacol 8: 108-111.
41. 3H-5-hydroxytryptamine release from rat brain slices and its presynaptic alpha-adrenergic modulation after long-term desipramine pretreatment. Naunyn Schmiedebergs Arch Pharmacol 318: 173-180.
42. Starke K (1977). Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol 77: 1-124.
43. Svensson TH, Bunney BS, Aghajanian GK (1975). Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res 92: 291-306.
44. Svensson TH, Usdin T (1978). Feedback inhibition of brain noradrenaline neurons by tricyclic antidepressants: alpha-receptor mediation. Science 202: 1089-1091.
45. Szabo ST, Blier P (2001). Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. Eur J Neurosci 13: 2077-2087.
46. 3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther 260: 427-436.
47. Valentino RJ, Wehby RG (1988). Morphine effects on locus coeruleus neurons are dependent on the state of arousal and availability of external stimuli: studies in anesthetized and unanesthetized rats. J Pharmacol Exp Ther 244: 1178-1186.
48. Westfall TC (1977). Local regulation of adrenergic neurotransmission. Physiol Rev 57: 659-728.
49. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP et al (2000). Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47: 818-829.
50. Wortley KE, Heal DJ, Stanford SC (1999). Modulation of sibutramine-induced increases in extracellular noradrenaline concentration in rat frontal cortex and hypothalamus by alpha2-adrenoceptors. Br J Pharmacol 128: 659-666.